Etzer Darout
Barclays Bank PLC, Research Division
Hello again, everyone. I’m Etzer Darout, senior biotech analyst at Barclays. It’s my pleasure to have Exelixis with us. With us today, we have Senior Vice President of Strategy and Investor Relations, Andrew Peters. Thank you so much for joining us. And I’m sure folks are familiar with the Exelixis story, but maybe it’d be helpful to maybe just start with some introductory remarks, and then we’ll go into Q&A.
Andrew Peters
Senior Vice President of Strategy
Sure. Thank you again for the invite. Always like being in Miami this time of year, even though the weather in California is also nice this week. As a reminder, we’re going to be making some forward-looking statements today. So please see disclosures around relative risks in our business in our SEC filings.
So Exelixis is a commercial oncology company, really built around our lead molecule, CABOMETYX, cabo which is a tyrosine kinase inhibitor that targets VEGF as well as a whole host of others, Met, Axl, MER, the TAM kinases, really kind of designed to be a best-in-class molecule across a wide range of indications. It’s approved in kidney cancer, liver cancer, thyroid cancer and now neuroendocrine tumors. And so it’s really kind of provided the foundation and a lot of the insights is to what we do at the company, both from a research and discovery perspective, but importantly from a strategic perspective as well. And I’m sure I’ll get to that a little bit later.
We did $2.123 billion in net product sales last year. We’ve guided
